Flurbiprofen transdermal - Tokuhon Corporation

Drug Profile

Flurbiprofen transdermal - Tokuhon Corporation

Alternative Names: Fulruban Pap; Stayban® Pap; Yakuban Tape

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Tokuhon Corporation
  • Developer GC-Rise Pharmaceutical; Tokuhon Corporation
  • Class Antipyretics; Antirheumatics; Nonsteroidal anti-inflammatories; Propionic acids
  • Mechanism of Action Cyclooxygenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Inflammatory pain; Muscle pain; Musculoskeletal disorders; Osteoarthritis; Periarthritis; Tendinitis
  • No development reported Pain

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top